C-J. Yen

482 total citations
7 papers, 102 citations indexed

About

C-J. Yen is a scholar working on Oncology, Otorhinolaryngology and Cancer Research. According to data from OpenAlex, C-J. Yen has authored 7 papers receiving a total of 102 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Otorhinolaryngology and 2 papers in Cancer Research. Recurrent topics in C-J. Yen's work include Head and Neck Cancer Studies (4 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Peptidase Inhibition and Analysis (3 papers). C-J. Yen is often cited by papers focused on Head and Neck Cancer Studies (4 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Peptidase Inhibition and Analysis (3 papers). C-J. Yen collaborates with scholars based in Taiwan, United States and Malaysia. C-J. Yen's co-authors include C-C. Lin, Yen‐Shen Lu, Wu‐Chou Su, Holger Fritsch, James Chih‐Hsin Yang, Kun‐Huei Yeh, Tillmann Taube, Ann‐Lii Cheng, Chih‐Hung Hsu and Victor Lee and has published in prestigious journals such as British Journal of Cancer and Annals of Oncology.

In The Last Decade

C-J. Yen

6 papers receiving 102 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C-J. Yen Taiwan 4 68 49 34 25 19 7 102
Camilla Borges Ferreira Gomes United States 5 21 0.3× 39 0.8× 16 0.5× 13 0.5× 6 0.3× 5 70
Aniket Shetty United States 2 51 0.8× 59 1.2× 12 0.4× 20 0.8× 3 0.2× 7 110
Genovefa Polychronidou Greece 4 41 0.6× 76 1.6× 14 0.4× 67 2.7× 2 0.1× 6 151
Laura Gibson United States 6 78 1.1× 59 1.2× 18 0.5× 31 1.2× 6 150
Quentin Campbell‐Hewson United Kingdom 5 56 0.8× 33 0.7× 20 0.6× 54 2.2× 13 101
Rana H. Besada United States 3 36 0.5× 56 1.1× 19 0.6× 17 0.7× 5 107
Federica Baldi Italy 3 57 0.8× 45 0.9× 4 0.1× 41 1.6× 3 0.2× 5 140
Wen-Hui Chen China 5 57 0.8× 42 0.9× 5 0.1× 14 0.6× 44 2.3× 8 124
Errin Samuëlsz United States 6 65 1.0× 70 1.4× 32 0.9× 22 0.9× 13 123
Ramona Crescenzo United States 4 52 0.8× 80 1.6× 12 0.4× 23 0.9× 5 116

Countries citing papers authored by C-J. Yen

Since Specialization
Citations

This map shows the geographic impact of C-J. Yen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C-J. Yen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C-J. Yen more than expected).

Fields of papers citing papers by C-J. Yen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C-J. Yen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C-J. Yen. The network helps show where C-J. Yen may publish in the future.

Co-authorship network of co-authors of C-J. Yen

This figure shows the co-authorship network connecting the top 25 collaborators of C-J. Yen. A scholar is included among the top collaborators of C-J. Yen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C-J. Yen. C-J. Yen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Yao, Herui, Min‐Hee Ryu, Jong Moon Park, et al.. (2023). 656MO The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study. Annals of Oncology. 34. S461–S462. 5 indexed citations
2.
3.
4.
Tahara, Makoto, Wan Zamaniah Wan Ishak, C-J. Yen, et al.. (2019). Phase III KEYNOTE-048 study of first-line (1L) pembrolizumab (P) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Asia vs non-Asia subgroup (subgrp) analysis. Annals of Oncology. 30. v461–v461. 1 indexed citations
5.
Ngamphaiboon, Nuttapong, Kaoru Tanaka, Ruey‐Long Hong, et al.. (2019). Phase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis. Annals of Oncology. 30. ix97–ix97. 3 indexed citations
6.
7.
Lin, C-C., Wu‐Chou Su, C-J. Yen, et al.. (2014). A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. British Journal of Cancer. 110(10). 2434–2440. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Camilla Borges Ferreira Gomes Breakdown of academic impact, for papers by Aniket Shetty Breakdown of academic impact, for papers by Genovefa Polychronidou Breakdown of academic impact, for papers by Laura Gibson Breakdown of academic impact, for papers by Quentin Campbell‐Hewson Breakdown of academic impact, for papers by Rana H. Besada Breakdown of academic impact, for papers by Federica Baldi Breakdown of academic impact, for papers by Wen-Hui Chen Breakdown of academic impact, for papers by Errin Samuëlsz Breakdown of academic impact, for papers by Ramona Crescenzo
Rankless by CCL
2026